Tissue-specific patterns of allelically-skewed DNA methylation

Sarah J. Marzi, Emma L. Meaburn, Emma L. Dempster, Katie Lunnon, Jose L. Paya-Cano, Rebecca G. Smith, Manuela Volta, Claire Troakes, Leonard C. Schalkwyk & Jonathan Mill

To cite this article: Sarah J. Marzi, Emma L. Meaburn, Emma L. Dempster, Katie Lunnon, Jose L. Paya-Cano, Rebecca G. Smith, Manuela Volta, Claire Troakes, Leonard C. Schalkwyk & Jonathan Mill (2016) Tissue-specific patterns of allelically-skewed DNA methylation, Epigenetics, 11:1, 24-35, DOI: 10.1080/15592294.2015.1127479

To link to this article: http://dx.doi.org/10.1080/15592294.2015.1127479
Tissue-specific patterns of allelically-skewed DNA methylation

Sarah J. Marzi\textsuperscript{a}, Emma L. Meaburn\textsuperscript{b}, Emma L. Dempster\textsuperscript{c}, Katie Lunnon\textsuperscript{c}, Jose L. Paya-Cano\textsuperscript{c}, Rebecca G. Smith\textsuperscript{c}, Manuela Volta\textsuperscript{a}, Claire Troakes\textsuperscript{a}, Leonard C. Schalkwyk\textsuperscript{d}, and Jonathan Mill\textsuperscript{a,c}

\textsuperscript{a}Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK; \textsuperscript{b}Department of Psychological Sciences, Birkbeck, University of London, London, UK; \textsuperscript{c}University of Exeter Medical School, University of Exeter, Exeter, UK; \textsuperscript{d}School of Biological Sciences, University of Essex, Colchester, UK

ABSTRACT
While DNA methylation is usually thought to be symmetrical across both alleles, there are some notable exceptions. Genomic imprinting and X chromosome inactivation are two well-studied sources of allele-specific methylation (ASM), but recent research has indicated a more complex pattern in which genotypic variation can be associated with allelically-skewed DNA methylation in \textit{cis}. Given the known heterogeneity of DNA methylation across tissues and cell types, we explored inter- and intra-individual variation in ASM across several regions of the human brain and whole blood from multiple individuals. Consistent with previous studies, we find widespread ASM with > 4% of the ~220,000 loci interrogated showing evidence of allelically-skewed DNA methylation. We identify ASM flanking known imprinted regions, and show that ASM sites are enriched in DNase I hypersensitivity sites and often located in an extended genomic context of intermediate DNA methylation. We also detect examples of genotype-driven ASM, some of which are tissue-specific. These findings contribute to our understanding of the nature of differential DNA methylation across tissues and have important implications for genetic studies of complex disease. As a resource to the community, ASM patterns across each of the tissues studied are available in a searchable online database: http://epigenetics.essex.ac.uk/ASMBrainBlood.

Introduction
DNA methylation is the most widely studied and stable epigenetic mark across the mammalian genome, playing a key role in the developmental regulation of gene expression. DNA methylation is generally symmetrical across both alleles, although exceptions characterized by allelic asymmetry include differentially methylated regions (DMRs) regulating the monoallelic expression of genes associated with X chromosome inactivation in females and genomic imprinting.\textsuperscript{1-5} Recently, it has been shown that the allelic-skewing of DNA methylation can also be driven by DNA sequence variation, with methylation quantitative trait loci (meQTLs) predominantly acting in \textit{cis}.\textsuperscript{6-11} ASM can be regarded as a special case of intermediate DNA methylation (IM), which has been found to occur in regions spanning a large portion of the human genome. It has been estimated that ASM contributes up to 18% of IM in the human genome.\textsuperscript{12}

DNA methylation patterns are highly dynamic during normal development and cellular differentiation.\textsuperscript{13-16} and tissue-specific patterns of DNA methylation have been widely studied in humans.\textsuperscript{17-20} In complex tissues such as the brain, for example, DNA methylation differentiates between functionally distinct regions\textsuperscript{21,22} and cell types.\textsuperscript{16,23-25} Patterns of IM can also be tissue-specific,\textsuperscript{12} with growing evidence for the widespread prevalence of tissue-specific ASM.\textsuperscript{27,28} In mouse, for example, it has been reported that 28% of imprinted genes are monoallelically expressed in a single tissue type, often the brain or extra-embryonic tissue.\textsuperscript{29} Examples of tissue-specifically imprinted genes include \textit{KCNQ1}, which becomes biallelically expressed in embryonic heart development,\textsuperscript{30} \textit{GNAS}, which is maternally expressed in a wide-range of tissues including the anterior pituitary, thyroid and ovaries but biallelically expressed in others, such as bone and visceral adipose tissue,\textsuperscript{31,32} and \textit{GRB10}, which is maternally expressed in most peripheral tissues but paternally expressed in the brain.\textsuperscript{29,33} Genetic influences on DNA methylation can also be tissue-specific, with meQTLs determining allelic patterns of methylation in \textit{cis} in certain tissues or cell types.\textsuperscript{11,34}

Increasing evidence supports a role for inter-individual variation in DNA methylation in the etiology and pathogenesis associated with a diverse range of complex disease phenotypes.\textsuperscript{35} Allelic differences in DNA methylation may be particularly important in this regard, acting as endophenotypes of genetic variation or additional epiallelic layers mediating the functional consequences of genotypic variation.\textsuperscript{36,37} Teasing apart genetic and non-genetic effects in a tissue- and cell type-specific manner will be a crucial step in understanding the association between non-coding genetic variation, DNA methylation, and complex disease.

To investigate the role of tissue-specific variation of ASM in the human brain and its relation to allelic biases in whole blood, we examined ASM across multiple brain regions and matched blood samples collected from multiple donors. Our data shows...
that although a large proportion of ASM is conserved across tissues, there are specific differences in the extent and distribution of ASM sites between regions of the brain and whole blood. Genome browser tracks displaying ASM signals as well as an online tool plotting ASM for sites of interest are available for download from a searchable database (http://epigenetics.essex.ac.uk/ASMBrainBlood).

Results

DNA methylation is allelically-skewed at specific locations across the genome

The majority of the genome is not characterized by notable allelic biases in DNA methylation in any of the tissues assessed in this study. The array-wide average of ASM score (in absolute values) is consistently low (mean = 0.025, range = 0.023 to 0.030) (Fig. S1A, Fig. S1B and Table S1). As expected, there is, however, evidence for allelically-biased DNA methylation at a notable number of specific genomic regions; in total 9,311 (4.22%) of the 220,449 informative SNPs in our assay show evidence for allelic-skewing of DNA methylation, defined by an absolute ASM score ≥ 0.10 in at least one tissue and individual. The percentage of amplicons characterized by an ASM score ≥ 0.10 in each of the 21 profiled samples is given in Table S2. The top-ranked loci showing evidence for allelically-skewed DNA methylation in whole blood, cerebellum, and cortex (BA9), and cerebellum are listed in Tables 1–3. Genome Browser tracks and an online ASM database are available from our laboratory website (http://epigenetics.essex.ac.uk/ASMBrainBlood).

Patterns of ASM in whole blood overlap with those identified in a previous study

In a previous study we characterized allelically-skewed DNA methylation in whole blood derived from 5 monozygotic twin pairs. There is a highly significant correlation between absolute ASM scores across all probes informative in both data sets (\( \rho = 0.21, P < 1.0 \times 10^{-50} \)) (Fig. S2), even though the majority of the probes do not exhibit ASM. Of the 2,704 ASM loci identified in Schalkwyk et al., 1,717 (63.50%) are informative in the current study, with a highly significant cross-study correlation of ASM scores at these probes (\( r = 0.52, P < 1.0 \times 10^{-50} \)). Likewise, there is a highly significant correlation between ASM scores across the two studies at sites showing allelically-skewed DNA methylation in blood in the current study which were also informative in our previous study (\( r = 0.38, P = 3.0 \times 10^{-28} \)). Of the 15 top-ranked blood ASM sites identified in our current study (Table 1), 7 of the 9 sites (78%) also informative in our previous study of ASM in blood\(^7\) were characterized by an absolute ASM score ≥ 0.10 in both analyses. These data confirm the validity of the MSNP approach for identifying allelically-skewed DNA methylation, reinforcing our previous conclusions about the extent of ASM in whole blood.

The extent and distribution of ASM differs across tissues

The average proportion of informative sites characterized by allelically-skewed DNA methylation (absolute ASM score ≥ 0.10) in each of the 8 tissues profiled was examined (Fig. 1A). Table 4 lists the top-ranked consistently allelically-skewed probes across cerebellum, whole blood, and cortex (BA9), with specific examples shown in Fig. 2A and Fig. 2B. Allelically-skewed DNA methylation appears to be consistently less prevalent in cortical regions (informative probes with ASM score ≥ 0.10 = 0.54%) compared to the cerebellum (1.14%) and whole blood (0.84%). The elevated level of allelically-skewed DNA methylation in the cerebellum and whole blood relative to cortex is more pronounced at more extreme ASM score thresholds (i.e., ASM score ≥ 0.20, cortex = 0.003%, cerebellum = 0.019%, whole blood = 0.013%) (Fig. S1C, Fig. S1D and Fig. S3). Of note, there is little variation in the prevalence and distribution of ASM scores between different regions of the cortex (average correlation between 2 cortical areas = 0.52, Fig. 1B and Fig. S4). We therefore selected one representative cortical region (BA9) for inclusion in subsequent analyses. In contrast, we find more striking differences between cortex, cerebellum and whole blood samples with inter-tissue correlations ranging from \( r = 0.42 \) to 0.48 (Figs. 1C-E). Table 5 lists the probes showing the highest level of variation in ASM scores across tissues with specific

Table 1. Top 15 ASM sites in whole blood, ASM score averaged across individuals.

| Rank | SNP ID      | Location     | Associated gene(s)     | Schalkwyk et al. (2010) | Blood ASM score | Cerebellum ASM score | BA9 ASM score |
|------|-------------|--------------|------------------------|-------------------------|-----------------|----------------------|--------------|
| 1    | SNP_A-2180729 (rs10276966) | 7p15.2       | HIBADH, EVXA\(^b\)    | 0.29                    | 0.25            | 0.01                 | 0.03          |
| 2    | SNP_A-8438077 (rs585451)  | 15q21.2      | ATPB4A, DTWD1          | NA                      | 0.25            | 0.01                 | 0.03          |
| 3    | SNP_A-1841543 (rs10234308) | 7p15.3       | MGC87042               | 0.34                    | 0.23            | 0.25                 | 0.23          |
| 4    | SNP_A-1946136 (rs927000)  | 2q13.12      | STK4                   | NA                      | 0.23            | 0.04                 | 0.01          |
| 5    | SNP_A-8450837 (rs44040867) | 16q12.2      | SLC6A2, LPCAT2         | 0.28                    | 0.22            | 0.05                 | 0.04          |
| 6    | SNP_A-4279002 (rs3355554) | 1q41         | CEBP5F, CKN2           | NA                      | 0.22            | 0.08                 | 0.09          |
| 7    | SNP_A-8450539 (rs10916799) | 1p36.12      | CAMKK1, LOC339505      | 0.18                    | 0.22            | 0.11                 | 0.15          |
| 8    | SNP_A-8633222 (rs13165930) | 5q33.3       | CCNL2                  | NA                      | 0.22            | 0.02                 | 0.12          |
| 9    | SNP_A-8472169 (rs11193683) | 10q23.1      | NRG3                   | 0.01                    | 0.22            | 0.09                 | 0.07          |
| 10   | SNP_A-2071005 (rs4687210) | 3q28         | UTS2D                  | NA                      | 0.22            | 0.16                 | 0.17          |
| 11   | SNP_A-2185394 (rs852454)  | 7p22.1       | HNF21                  | 0.06                    | 0.22            | 0.11                 | 0.11          |
| 12   | SNP_A-8702215 (rs12978268) | 19p13.11     | FCHD1, MAP1S           | 0.19                    | 0.22            | 0.00                 | 0.07          |
| 13   | SNP_A-1807006 (rs10481354) | 8p23.3       | CLNB, DLGAP6\(^a\)     | 0.22                    | 0.22            | 0.00                 | 0.05          |
| 14   | SNP_A-8326632 (rs1542180) | 2q31.1       | HOXD3, HOXD4           | NA                      | 0.21            | 0.24                 | 0.19          |
| 15   | SNP_A-2008150 (rs869108)  | 11p15.1      | OTOG, MYO1, USH1C      | 0.22                    | 0.21            | 0.16                 | 0.07          |

a Known imprinted gene  
b Suspected imprinted gene
Table 2. Top 15 ASM sites in cerebellum, ASM score averaged across individuals.

| Rank | SNP ID         | Location  | Associated gene(s) | Cerebellum ASM score | Blood ASM score | BA9 ASM score |
|------|----------------|-----------|-------------------|----------------------|-----------------|---------------|
| 1    | SNP_A-4255628  | 18q12.3   | SL1C4A2, SETBP1    | 0.30                 | 0.03            | 0.05          |
| 2    | SNP_A-8696273  | 5q31.1    | C5orf56           | 0.29                 | 0.16            | 0.07          |
| 3    | SNP_A-1820553  | 12q22     | CLU1OS, BTG1       | 0.26                 | 0.03            | 0.05          |
| 4    | SNP_A-18241453 | 7p15.3    | MGCG87042         | 0.25                 | 0.23            | 0.23          |
| 5    | SNP_A-2002288  | 10q22.1   | COL13A1, C10orf35 | 0.24                 | 0.10            | 0.10          |
| 6    | SNP_A-8625237  | 12q49005  | TBL1XR1           | 0.24                 | 0.20            | 0.24          |
| 7    | SNP_A-8326632  | 15q24180  | HOXD3, HOXD4      | 0.24                 | 0.21            | 0.19          |
| 8    | SNP_A-2160121  | 16q23.3   | CDH13, MPHOSPH6    | 0.24                 | 0.01            | 0.01          |
| 9    | SNP_A-2052542  | 3q13.2    | MAP1B             | 0.24                 | 0.04            | 0.19          |
| 10   | SNP_A-2040586  | 14q22.2   | BCL11B, C14orf177 | 0.23                 | 0.10            | 0.18          |
| 11   | SNP_A-8420373  | 2p22.1    | TMMT1P8           | 0.23                 | 0.01            | 0.07          |
| 12   | SNP_A-1788157  | 7p158663  | MEG6*             | 0.23                 | 0.01            | 0.03          |
| 13   | SNP_A-4235630  | 7q31.2    | TFCe, MDFC        | 0.23                 | 0.05            | 0.13          |
| 14   | SNP_A-4264548  | 4q27      | TRPC3, KIA1109    | 0.23                 | 0.01            | 0.00          |
| 15   | SNP_A-1931666  | 2q34      | ICF2, ERBB4       | 0.22                 | 0.03            | 0.02          |

* Known imprinted gene

Table 3. Top 15 ASM sites in cortex (BA9), ASM score averaged across individuals.

| Rank | SNP ID         | Location  | Associated gene(s) | BA9 ASM score | Cerebellum ASM score | Blood ASM score |
|------|----------------|-----------|-------------------|---------------|----------------------|-----------------|
| 1    | SNP_A-8625237  | 3q26.32   | TBL1XRX1          | 0.24          | 0.24                 | 0.20            |
| 2    | SNP_A-8463467  | 7q35      | OR2F2, OR2F1      | 0.23          | 0.17                 | 0.17            |
| 3    | SNP_A-1841543  | 7p15.3    | MGCG87042         | 0.23          | 0.25                 | 0.23            |
| 4    | SNP_A-8652219  | 1p26.31   | FHAD1             | 0.22          | 0.13                 | 0.18            |
| 5    | SNP_A-8301602  | 3p25.3    | SGRAP3, RAD18     | 0.21          | 0.18                 | 0.21            |
| 6    | SNP_A-2107016  | 6q21      | AIM1, AG5         | 0.20          | 0.16                 | 0.15            |
| 7    | SNP_A-2052542  | 5q13.2    | MAP1B             | 0.19          | 0.24                 | 0.04            |
| 8    | SNP_A-2307481  | 7p15691   | LOC400456, MCTP2  | 0.19          | 0.21                 | 0.17            |
| 9    | SNP_A-8643280  | 3q12.11   | HFE2, NBP10       | 0.19          | 0.17                 | 0.15            |
| 10   | SNP_A-8326632  | 5q14180   | HOXD3, HOXD4      | 0.19          | 0.24                 | 0.21            |
| 11   | SNP_A-1998203  | 9q34.11   | TOR1B, PTGES      | 0.19          | 0.15                 | 0.19            |
| 12   | SNP_A-8640607  | 3q27.1    | MCF2L2            | 0.18          | 0.11                 | 0.07            |
| 13   | SNP_A-4291638  | 7p13      | YK76              | 0.18          | 0.19                 | 0.01            |
| 14   | SNP_A-1892234  | 5p12      | MGC42105          | 0.18          | 0.11                 | 0.03            |
| 15   | SNP_A-8653671  | 8p21.3    | TNFRSF10D         | 0.18          | 0.09                 | 0.11            |

* Known imprinted gene

examples shown in Fig. 3A and Fig. 3B. We used clonal bisulite sequencing to validate tissue-specific ASM identified by the MSNP method in these 2 regions (Fig. 3C and Fig. 3D), confirming the patterns observed in our array data for both loci.

Informative MSNP probes within DNase I hypersensitive regions are characterized by elevated ASM scores

Enrichment analyses were performed using a Kruskal-Wallis rank-sum test for ASM rank differences between the annotated genic regions (see Materials and Methods). We observed a differential distribution of ASM scores across annotated genic regions (i.e., coding, 5’UTR, intergenic, intron, promoter, 3’UTR) in cortex (BA9) (P = 1.29 × 10−15), cerebellum (P = 3.98 × 10−14), whole blood (P = 2.06 × 10−12), and the cross-tissue analysis (P = 2.12 × 10−26). Post-hoc tests identified these differences to be primarily driven by an enrichment of high ASM scores in promoter regions (Fig. S5). We used data from ENCODE38 to assess whether ASM is enriched in regions associated with DNase I hypersensitive (DHS) sites identified in multiple tissues including frontal cortex and cerebellum, as well as CD14+ monocytes and naïve B cells (as a proxy for blood). We compared the ASM score ranks for informative probes between regions defined by the presence or absence of DHS sites using a Wilcoxon rank-sum test (see Materials and Methods). DHS peaks across all tissues are enriched for higher ASM scores identified in cortex (BA9), cerebellum, and whole blood (Table S3 and Fig. S6). Of note, the most striking enrichment is found for cerebellum ASM scores in regions characterized by cerebellum DHS peaks in ENCODE (P = 3.51 × 10−220).

Inter-individual variation in ASM

We next examined inter-individual differences in ASM score at specific loci, defining probes with a large range of ASM scores across the 3 individuals as being characterized by “variable ASM.” Differentially methylated regions (DMRs) associated with genomic imprinting, for example, are characterized by parental-origin-specific ASM and are expected to show consistently large ASM scores that exhibit allelic-flipping, resulting from genotype-independent ASM. Genotype-driven ASM, in contrast, is likely to be exemplified by consistent allelic biases in DNA methylation across individuals, and is generally not variable between individuals of the same genotype. Fig. S7 shows the correlation in ASM scores across the 3 individuals profiled by MSNP, with tissue-specific correlations given in Table S4. As expected, the individuals were more highly correlated for loci characterized by high ASM scores. For probes informative in at least 2 individuals we examined the range of
in many of these regions because they were only informative (i.e., heterozygous) in a single individual. Notably, we also identified allelic-flipping in the vicinity of loci not previously characterized as being imprinted, for example WRB (Fig. 4D) and ITPKI (Fig. S9). Other variable ASM sites are marked by both high and low ASM scores in different individuals, rather than allelic-flipping between them, for example, MGST3/LOC400794 (Table S5). Interestingly, we identified a number of sites characterized by tissue-specific variable ASM. A notable example is the imprinted gene GRB10, which has been previously shown to be differentially maternally- and paternally-expressed in a tissue-specific manner (Fig. S8F).

**Variable ASM sites are flanked by extended regions of intermediate DNA methylation**

We next quantified genome-wide patterns of DNA methylation in a larger sample (n=39) of matched whole blood, cortex (BA9), and cerebellum samples using the Illumina Infinium HumanMethylation450 BeadChip (450K array). For the 100 top-ranked ASM sites in each of the 3 tissues, plus the 100 top-ranked cross-tissue, tissue-specific, and variable ASM sites we identified probes on the array located within 1 kb of the ASM marker SNPs (Table S8; detailed in Table S9–S17) to investigate patterns of DNA methylation across an extended region. As expected, regions around known imprinted loci identified by our ASM analysis are flanked by extended regions of intermediate DNA methylation (i.e., average levels of DNA methylation between 0.4 and 0.6) (Fig. 5A and Fig. 5B). We observe a highly significant enrichment (P range = 6.82 × 10−11 – 0.005) of intermediate DNA methylation relative to overall levels identified on the 450K array in regions flanking variable ASM sites in all 3 tissues (Table 7 and Fig. 6). For example, intermediate DNA methylation was observed around the variable ASM site overlapping WRB (Fig. 5C), that showed evidence of allelic-flipping (Fig. 4D). Another probe exhibiting variable ASM annotated to TGFBI/VTRNA2-1 on chromosome 5 also shows a similar pattern of intermediate DNA methylation (Fig. 5D). Interestingly, 4 individuals are distinguished by consistent hypomethylation in whole blood and cortex across 16 of the 19 sites, consistent with previous reports describing polymorphic imprinting of this locus.

**Identification of tissue-specific genotype-driven ASM**

In contrast to the intermediate DNA methylation patterns enriched in the vicinity of variable ASM sites, non-variable ASM (i.e., characterized by consistent ASM scores across individuals) is not significantly enriched for intermediate DNA methylation and in some cases is exemplified by trimodal patterns of DNA methylation, which are highly suggestive of genotype-driven ASM acting in cis. Of note, we also observe examples of tissue-specific genotype-driven ASM. For example, a tissue-specific ASM site identified as showing allelically-skewed DNA methylation in cerebellum (ASM score = 0.16) but not whole blood (ASM score = 0.03) or cortex (ASM score = 0.04) (Fig. 7A) located in an intron of the gene SYNJ2 is
flanked by trimodal levels of DNA methylation in cerebellum but not blood or cortex (Fig. 7B).

**Discussion**

This study confirms the relatively widespread distribution of allelically-skewed DNA methylation in the human genome, corroborating our previous data generated in whole blood. We also present evidence for tissue-specific differences in the quantity and distribution of ASM between different regions of the human brain, and between brain and whole blood. Our findings are in line with previous reports, confirming the importance of tissue-specific DNA methylation profiles across the brain. 

Although our data confirm previous studies, identifying more between-tissue variation than inter-individual variation, we find clear examples where ASM is variable between individuals. While the number of samples profiled in this study is too small to accurately determine how much of the observed inter-individual variation in ASM results from genetic and non-genetic effects, previous studies suggest that the majority of such variation is likely to be genetically driven. Interestingly, we identify instances of tissue-specific allelically-skewed DNA methylation resulting from both genomic imprinting and genotypic effects. For example, we observe tissue-specific variable ASM around the imprinted growth factor receptor-bound protein 10 gene (*GRB10*), which encodes a protein that interacts with insulin-like growth factors and we observe genotype-driven ASM exclusively in cerebellum for several probes within the synaptotagmin 2 gene (*SYNJ2*), which encodes a protein involved in the uncoating of vesicles. Such tissue-specific ASM has important implications for epigenetic epidemiology, and provides a mechanism by which genotype may exert an effect on gene function and regulation in a tissue-specific manner.

This study has a number of important limitations. First, although we used a unique set of samples comprising of matched tissues obtained from the same donors, the number of individuals profiled in our analysis was small, meaning we cannot definitively distinguish between genetic and non-genetic effects, or make broad statements about general patterns of inter-individual variation of ASM. Our Illumina 450K array validation studies were undertaken in a larger set of individuals, but could only confirm intermediate levels of DNA methylation and not detect allele-specific patterns. Second, given the limited availability of RNA from the same samples, we were unable to relate our ASM findings to allelic patterns of gene expression in the same individuals. Previous studies, however, have shown that ASM is linked to allele-specific expression of nearby genes. Third, our analyses were undertaken on whole tissue, and represent aggregate values across a number of individual cell types. Fourth, the MSNP approach utilizes SNP

| Rank | SNP ID       | Location | Associated gene(s) | Cerebellum ASM score | Blood ASM score | BA9 ASM score | Tissue average |
|------|--------------|----------|-------------------|----------------------|----------------|--------------|---------------|
| 1    | SNP_A-1841543 (rs10234308) | 7p15.3   | MGC87042           | 0.25                 | 0.23           | 0.23         | 0.24          |
| 2    | SNP_A-8625237 (rs12493005)  | 3q26.32  | TBL1XR1            | 0.24                 | 0.20           | 0.24         | 0.22          |
| 3    | SNP_A-8326632 (rs1542180)   | 2q31.1   | HOXD3, HOXD4       | 0.24                 | 0.21           | 0.19         | 0.21          |
| 4    | SNP_A-8301062 (rs3982225)   | 3p25.3   | RAD1F, RAD19       | 0.18                 | 0.21           | 0.21         | 0.20          |
| 5    | SNP_A-8463467 (rs17164474)  | 7q35     | OR2F2, OR2F1       | 0.17                 | 0.17           | 0.23         | 0.19          |
| 6    | SNP_A-2307481 (rs176591)    | 15q26.2  | MCTP2, LOC400456  | 0.21                 | 0.17           | 0.19         | 0.19          |
| 7    | SNP_A-1894705 (rs986324)    | Xp22.11  | DDX15, ZNF645      | 0.18                 | 0.20           | 0.17         | 0.18          |
| 8    | SNP_A-2071005 (rs49687210)  | 3q28     | UT52D              | 0.16                 | 0.22           | 0.17         | 0.18          |
| 9    | SNP_A-1998023 (rs9722212)   | 9q34.11  | PTGES, TOR1B       | 0.15                 | 0.19           | 0.19         | 0.18          |
| 10   | SNP_A-8652129 (rs2479084)   | 1p36.21  | PHAD1              | 0.13                 | 0.18           | 0.22         | 0.18          |
| 11   | SNP_A-8696273 (rs1003533)   | 5q31.1   | CSR5F              | 0.29                 | 0.16           | 0.07         | 0.17          |
| 12   | SNP_A-1862496 (rs17578280)  | 1p31.1   | LRRIQ5, NEGR1      | 0.18                 | 0.17           | 0.17         | 0.17          |
| 13   | SNP_A-2040586 (rs17097287)  | 14q32.2  | CI4orf177, BCL11B  | 0.23                 | 0.10           | 0.18         | 0.17          |
| 14   | SNP_A-1932077 (rs2200030)   | 15q11.2  | SRNP1              | 0.18                 | 0.18           | 0.15         | 0.17          |
| 15   | SNP_A-2107106 (rs9873777)   | 6q21     | AIM1*, ATG5        | 0.16                 | 0.15           | 0.20         | 0.17          |

* Known imprinted gene

Figure 2. Multiple loci are characterized by consistent allelic-skewing of DNA methylation across all tissues. Heatmaps display allele signal intensities for genomic DNA (G), MSRE-digested DNA (D) and fully unmethylated, MSRE-digested DNA (U) in all tissues. A and B denote the 2 alleles of the SNP and brightness represents the quantile normalized signal intensity, with the scale displayed below the heatmap. Shown are the 2 top-ranked probes characterized by consistent ASM across tissues. These two probes were informative in (A) individual 2 for rs10234308 and (B) individual 3 for rs12493005.
microarrays—these do not interrogate the whole genome, and can only assess pools of DNA molecules. Allelic patterns of DNA methylation across individual DNA molecules cannot be directly assessed using this approach, as would be possible using bisulfite-sequencing methods. Furthermore, our threshold for calling allelic imbalances in DNA methylation is

### Table 5. Top 15 tissue-specific ASM sites, defined by highly variable ASM scores across cerebellum, whole blood, and cortex (BA9).

| Rank | SNP ID     | Location       | Associated gene(s) | Cerebellum ASM score | Blood ASM score | BA9 ASM score | SD   |
|------|------------|----------------|-------------------|----------------------|----------------|---------------|------|
| 1    | SNP_A-4255628 (rs959246) | 18q12.3 | SLC14A2, SETBP1   | -0.30 | -0.03 | -0.05 | 0.15 |
| 2    | SNP_A-1946136 (rs927000) | 19q13.12 | STK4 | -0.04 | 0.23 | 0.01 | 0.15 |
| 3    | SNP_A-8438077 (rs585451) | 15q21.2 | ATP8B4, DTWD1 | 0.01 | -0.25 | 0.00 | 0.15 |
| 4    | SNP_A-8397727 (rs1123514) | 5q13.3 | ENCl, RGNEF | -0.16 | 0.11 | -0.01 | 0.13 |
| 5    | SNP_A-2273838 (rs2252267) | 14q23.1 | PRKCN | 0.19 | -0.03 | -0.05 | 0.13 |
| 6    | SNP_A-4264458 (rs1358229) | 4q27 | TRPC3, KIAA1109 | -0.23 | 0.01 | 0.00 | 0.13 |
| 7    | SNP_A-8643616 (rs11700515) | 21q22.3 | COL6A1, PCBP3 | 0.20 | -0.01 | -0.03 | 0.13 |
| 8    | SNP_A-2180729 (rs10276966) | 7p15.2 | HIBADH, EXV1b | -0.01 | -0.25 | -0.03 | 0.13 |
| 9    | SNP_A-4210659 | (rs10517764) | 4q32.2 | NAF1, FSTLS | 0.07 | -0.14 | -0.15 | 0.13 |
| 10   | SNP_A-1997081 (rs10512149) | 9q21.33 | SLC28A3, NTRK2 | -0.19 | 0.02 | 0.05 | 0.13 |
| 11   | SNP_A-2160121 (rs205794) | 16q23.3 | CDH13, MPHOSPH6 | -0.24 | -0.01 | -0.01 | 0.13 |
| 12   | SNP_A-8667432 (rs19782) | 1p36.11 | CTOR2F1 | 0.19 | -0.04 | -0.01 | 0.13 |
| 13   | SNP_A-1787058 (rs10951911) | 7p12.3 | TN53, C1orf65 | -0.20 | -0.01 | 0.04 | 0.13 |
| 14   | SNP_A-1931666 (rs6707698) | 2q34 | IKZF2, ERBB4 | -0.22 | -0.03 | 0.02 | 0.13 |
| 15   | SNP_A-8502638 (rs10989120) | 9q31.1 | TMEFF1, CTOR30 | 0.04 | -0.20 | -0.15 | 0.13 |

b Suspected imprinted gene

Figure 3. A number of loci are characterized by allelic-skewing of DNA methylation in only one tissue with minimal ASM present in any of the other tissues examined. Heatmaps display allele signal intensities for genomic DNA (G), MSRE-digested DNA (D) and fully unmethylated, MSRE-digested DNA (U) in all tissues. A and B denote the 2 alleles of the SNP and brightness represents the quantile normalized signal intensity, with the scale displayed below the heatmap. Two of the top-ranked cerebellum-specific ASM signals are (A) rs959246 (informative for individual 3) and (B) rs2252267 (informative for individual 2). The tissue-specific patterns of DNA methylation in these 2 loci were validated by clonal bisulfite sequencing, confirming the findings from the MSNP assay (C,D). Each row represents a single DNA molecule, with black dots depicting methylated cytosines and white dots depicting unmethylated cytosines. The percentage of methylated cytosines for each sample is displayed below the plots. The amplicon spanning the DMR associated with rs959246 in (C) did not encompass a SNP enabling us to distinguish between the 2 alleles, however the methylation pattern shows evidence for tissue-specific intermediate methylation (IM) in the cerebellum. G and A in (D) denote the 2 alleles determined by SNP variation within the amplicon in heterozygous individual 2. Cerebellum-specific hypomethylation of the A allele is observed surrounding rs2252267, with individual 3 (homozygous for the G allele) being highly methylated in all 3 tissues.
somewhat arbitrary; it is likely that our data is confounded by both false positives and negatives. We did, however, find very consistent overlap in whole blood ASM data with that reported in our previous study using the same laboratory and analysis methods, confirming the validity of the MSNP approach. Furthermore, we validated our findings using 2 independent platforms: clonal bisulfite sequencing and the Illumina 450K Human methylation array. Using the latter, we were able to show that variable ASM sites are located in an extended context of intermediate DNA methylation, supporting a regional regulatory role of DNA methylation in these domains, which is potentially driving intermediate expression levels in a quantitative manner across gene regulation clusters.

Table 6. Top 15 variable ASM sites, defined by average range of ASM scores between individuals across cerebellum, whole blood, and cortex (BA9).

| Rank | SNP ID | Location | Associated gene(s) | Cerebellum range | Blood range | BA9 range | Average range |
|------|--------|----------|--------------------|------------------|-------------|-----------|---------------|
| 1    | SNP_A-8579417 (rs1538116) | 1q24.1 | MGST3, LOC400794 | 0.24 | 0.35 | 0.32 | 0.30 |
| 2    | SNP_A-2019421 (rs2244352) | 21q22.2 | WRB | 0.36 | 0.24 | 0.29 | 0.30 |
| 3    | SNP_A-4219174 (rs2346019) | 3q11.1 | TGFB1, VTRNA2b | 0.23 | 0.23 | 0.30 | 0.25 |
| 4    | SNP_A-4208914 (rs2417651) | 20q13.2 | CYP24A1 | 0.25 | 0.23 | 0.17 | 0.22 |
| 5    | SNP_A-8717059 (rs22013066) | 2p13.3 | ARHGAP25 | 0.26 | 0.15 | 0.21 | 0.21 |
| 6    | SNP_A-8692937 (rs4605656) | 4q24 | CXXC4, TACR3 | 0.16 | 0.18 | 0.25 | 0.20 |
| 7    | SNP_A-8634251 (rs1109228) | 14q24.2 | RG56, SPPA1L1 | 0.19 | 0.15 | 0.24 | 0.19 |
| 8    | SNP_A-8329713 (rs16825906) | 3q13.31 | LSAMP, IGSF11, LOC285194 | 0.21 | 0.13 | 0.22 | 0.19 |
| 9    | SNP_A-8713358 (rs1680883) | 4p15.33 | CPEB2, LOC152742 | 0.24 | 0.14 | 0.17 | 0.19 |
| 10   | SNP_A-8638348 (rs1522744) | 2p21 | SRBD1 | 0.20 | 0.18 | 0.17 | 0.18 |
| 11   | SNP_A-1855770 (rs2764124) | 13q34 | CUL4A | 0.16 | 0.23 | 0.15 | 0.18 |
| 12   | SNP_A-4259064 (rs7766133) | 6p22.3 | MOAT1 | 0.17 | 0.17 | 0.20 | 0.18 |
| 13   | SNP_A-2118217 (rs1695824) | 1p36.33 | VWA1, TMEM88B | 0.25 | 0.16 | 0.13 | 0.18 |
| 14   | SNP_A-1880775 (rs6116750) | 20p12.3 | PROKR2 | 0.23 | 0.13 | 0.18 | 0.18 |
| 15   | SNP_A-8424056 (rs3942835) | 9q22.1 | CDH2, CHST9 | 0.18 | 0.04 | 0.32 | 0.18 |

b Suspected imprinted gene
characterized by DHS peaks across several tissues. This enrichment of ASM in the vicinity of markers of open chromatin supports the involvement of ASM in transcriptional activity.

To conclude, we explored inter- and intra-individual variation in ASM across several regions of the human brain and whole blood from multiple individuals. Consistent with previous studies, we find relatively widespread ASM, observing allelically-skewed DNA methylation flanking known imprinted regions, and show that ASM sites are often located in an extended genomic context of intermediate DNA methylation. Interestingly, we detect cases of genotype-driven ASM, which are also tissue-specific. These findings contribute to our understanding about the nature of differential DNA methylation across tissues and have important implications for genetic studies of complex disease.

As a resource to the community, ASM patterns across each of the tissues studied are available in a searchable online database: http://epigenetics.essex.ac.uk/ASMBrainBlood.

### Materials and methods

**Genome-wide analysis of allelically-skewed DNA methylation**

Post-mortem brain and pre-mortem whole blood samples from 2 female and one male donors were provided by the MRC London Neurodegenerative Disease Brain Bank (http://www.kcl.ac.uk/ioppn/depts/bcn/Our-research/Neurodegeneration/brain-bank.aspx). Subjects were approached in life for written consent for

---

**Table 7. Enrichment in intermediate methylation (IM) near ASM regions.**

| Tissue  | IM rate | O/E | P     |
|---------|---------|-----|-------|
| Blood   | 5.88%   | 0.98| 0.576 |
| Cerebellum | 11.49% | 1.75| 0.059 |
| BA9     | 13.29%  | 1.45| 0.065 |
| Cross-tissue | 8.11%  | 0.87| 0.741 |
| Tissue-specific | 8.00%  | 0.85| 0.701 |
| Variable | 38.46%  | 4.10| 9.56 \times 10^{-11} |
| Variable (BA9) | 37.50%  | 4.09| 8.66 \times 10^{-9} |
| Variable (cerebellum) | 16.95%  | 2.58| 0.005 |
| Variable (blood) | 34.48%  | 5.77| 6.82 \times 10^{-11} |

---

IM is defined as an average methylation between 0.4 and 0.6, enrichment P values are based on a hypergeometric test based on the background distribution of IM.

We used tissue-specific background distributions for ASM types based on single tissues.
brain banking, and all tissue donations were collected and stored following legal and ethical guidelines (NHS reference number 08/MRE09/38; the HTA license number for the LBBND brain bank is 12293). All samples were free from neuropathological and neuropsychiatric disease. A detailed list of brain regions obtained for each individual is provided in Table S18. Genomic DNA was isolated from all tissue samples using a standard phenol-chloroform protocol and assessed for purity and degradation prior to analysis (see Davies et al. for additional information about the samples used in this study). The MSNP method, described previously, was used to quantitatively assess allelic-skewing of DNA methylation across the genome. Briefly, Affymetrix Genome-wide Human SNP 6.0 Arrays were used to genotype a) DNA from each tissue sample digested with a cocktail of MSREs (HpaII: 5'-C CG G-3', HhaI: 5'-G CG C-3', and AciI: 5'-C CG G C-3') (D arrays), b) unmethylated whole-genome-amplified DNA for each individual digested with the same cocktail of MSREs to control for possible confounding effects of DNA sequence polymorphisms located at MSRE cut-sites (U arrays), and c) genomic DNA from each of the 3 individuals to identify heterozygous (informative) SNPs (G arrays). Unmethylated DNA was produced by whole-genome amplifying 100 ng cerebellum DNA using the Qiagen RepliG kit (Qiagen, Crawley, UK) using the manufacturer’s protocol. In total 28 genotyping arrays were processed: 22 D arrays (DNA from between 6 and 7 brain regions plus whole blood, for each individual), 3 U arrays (one for each individual), and 3 G arrays (one for each individual). Additional methodological details are available in Schalkwyk et al.

Selection of informative SNPs and quantification of ASM

To be informative in the ASM assay, SNPs must be heterozygous, and the amplicon must contain an MSRE cut site. To guard against poorly performing SNP probes we also removed consistently low signal intensity SNPs across the 22 G arrays, and those yielding a highly variable U/G signal ratio (SD > 0.077) across all samples. A total of 220,449 SNPs passed our stringent filtering criteria and were classified as informative and heterozygous in at least one individual. The number of informative SNPs in each of the individual samples profiled by the MSNP method is shown in Table S19. Quantitative measures of ASM were derived by comparing signal intensities between the D (MSRE digested) and G (genomic DNA) arrays using the SNPMaP package (v1.02) in R that was developed for the estimation of allele frequencies in DNA pools genotyped on SNP arrays. Briefly, relative allele score (RAS) values were generated for all SNPs on the array, which are defined as A/(A + B), where A and B are the intensities of the probes for the 2 alleles of

Figure 6. Regions around variable ASM are enriched in intermediate DNA methylation. The distributions of DNA methylation at the 65 Illumina 450K Human Methylation Array probes within 1 kb of the top 100 variable ASM sites (Table S14) show an enrichment in intermediately methylated probes compared to DNA methylation levels across the whole array (shown in gray) in (A) cortex (BA9), (B) cerebellum, and (C) whole blood.

Figure 7. Genotype-driven ASM can be tissue-specific. (A) The tissue-specific ASM site rs1009014, located in an intron of SYNJ2, shows allelic-skewing of DNA methylation in cerebellum (ASM score = 0.16) but not in cortex (ASM score = 0.04) or whole blood (ASM score = 0.03). (B) DNA methylation levels for Illumina 450K Human Methylation Array probes in cerebellum across a flanking region of this locus exhibit a genotype-driven tissue-specific DNA methylation pattern. The scatter plot shows the location of SYNJ2 (transcript variant 1), as well as the location of the informative SNP from the MSNP assay (gray vertical line).
a given SNP. For a given SNP in a heterozygous individual, ASM (or allelic-skewing of DNA methylation) is detected as a difference in RAS “ASM score” and define probes showing an absolute ASM score ≥ 0.10 as “allelically-skewed.” A UCSC custom annotation track showing the location of all 220,449 loci and the degree of allelic-skewing in DNA methylation across each tissue and individual is available for download from our website (http://epigenetics.essex.ac.uk/ASMBrainBlood). Enrichment analyses were performed using a Kruskal-Wallis rank-sum test for ASM rank differences between the annotated genic regions. This non-parametric method tests whether multiple samples were analyzed using a Kruskal-Wallis rank-sum test (http://epigenetics.essex.ac.uk/ASMBrainBlood). Enrichment and individual is available for download from our website.

Following sodium bisulfite sequencing analysis to further verify our findings and determine the precise allele-specific patterns of DNA methylation. Following sodium bisulfite treatment and bisulfite-PCR amplification, amplicons were cloned using the TOPO TA cloning method (Invitrogen, Paisley, UK) and sequenced with BigDye v1.1 sequencing chemistry (Applied Biosystems) (Table S20). A Nemenyi test for pairwise multiple comparisons of mean rank sums as implemented in the PMCMR R package was used for post-hoc comparisons.

EnCODE tracks for DHS peaks in frontal cortex, frontal cerebrum, cerebellum, CD14+ monocytes, naive B cells, H1 human embryonic stem cells (H1-hesc), heart, and fibroblasts were obtained from the UCSC genome browser (http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeDpenChromDnase/). For the DHS enrichment analyses we tested whether the rank-sums for ASM scores differed significantly in informative probes defined by the presence or absence of DHS peaks using a Wilcoxon rank-sum test. Informative probes were ranked according to ASM scores with higher absolute ASM scores corresponding to lower ranks.

Clonal bisulfite sequencing

Two regions were subsequently selected for clonal bisulfite sequencing analysis to further verify our findings and determine the precise allele-specific patterns of DNA methylation. Following sodium bisulfite treatment and bisulfite-PCR amplification, amplicons were cloned using the TOPO TA cloning method (Invitrogen, Paisley, UK) and sequenced with BigDye v1.1 sequencing chemistry (Applied Biosystems) (Table S20). Sequencing traces were visualized, quality controlled, and aligned using BiQ Analyzer. All data were tested for complete bisulfite conversion, with an overall conversion rate > 99.9% estimated by BiQ Analyzer.

Validation of ASM on the Illumina 450K HumanMethylation microarray

Further analysis of ASM sites was undertaken on a larger collection of post-mortem brain samples (n = 34), comprising BA9, BA21, BA28/34, and cerebellum, which were also free of any neuropathology and neuropsychiatric disease. Additionally we analyzed matched pre-mortem whole blood samples, which were available for a subset (n = 8), as well as 5 unmatched blood samples (see Table S18). The 3 individuals profiled by MSNP were included in this analysis. DNA (500 ng) from each sample was treated with sodium bisulfite in duplicate, using the EZ-96 DNA methylation kit (Zymo Research, CA, USA). DNA methylation was quantified using the Illumina Infinium HumanMethylation450 BeadChip (Illumina Inc., CA, USA) run on an Illumina HiScan System (Illumina) using the manufacturers’ standard protocol, with pre-processing and stringent quality control performed as previously described. We used the GenomicRanges package to extract data for all CpG sites within 1 kb of candidate ASM SNPs and examined patterns of DNA methylation across the 3 tissues. Intermediate DNA methylation was defined as an average methylation value between 0.4 and 0.6 across all individuals. To test for statistical significance of enrichment in intermediate methylated probes we used a hypergeometric distribution based on the number of probes tested and the background of intermediate methylated probes across the whole array. Annotation of genes in the methylation plots (Fig. 5 and Fig. 7B) was obtained from the UCSC Genome Browser hg19 assembly. Imprinting control region (ICR) annotation was obtained from the web resource on human DMRs provided by the Department of Medical and Molecular Genetics, Kings College London (https://atlas.genet ics.kcl.ac.uk) and lifted over from hg18 to hg19.

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Acknowledgments

This work was supported by grants from the UK Medical Research Council (MRC) (grant number MR/K013807/1) and US National Institutes of Health (grant number AG036039) to JM. SJM is funded by the EU-FP7 project EpiTrain (REA grant agreement n° 316758).

References

1. Ferguson-Smith AC, Sasaki H, Cattanach BM, Surani MA. Parental-origin-specific epigenetic modification of the mouse H19 gene. Nature 1993; 362:751-5; PMID:8469285; http://dx.doi.org/10.1038/362751a0
2. Wutz A, Smrcka OW, Schweifer N, Schellander K, Wagner EF, Barlow DP. Imprinted expression of the Igf2r gene depends on an intronic CpG island. Nature 1997; 389:745-9; PMID:9338788; http://dx.doi. org/10.1038/39631
3. Lee JT, Bartolomei MS. X-inactivation, imprinting, and long noncoding RNAs in health and disease. Cell 2013; 152:1308-23; PMID:23498939; http://dx.doi.org/10.1016/j.cell.2013.02.016
4. Ferguson-Smith AC. Genomic imprinting: the emergence of an epigenetic paradigm. Nat Rev Genet 2011; 12:565-75; PMID:21765458; http://dx.doi.org/10.1038/nrg3032
5. Barlow DP, Bartolomei MS. Genomic imprinting in mammals. Cold Spring Harbor Perspect Biol 2014; 6:pii: a013832; http://dx.doi.org/10.1101/cshperspect.a013832
6. Kerkel K, Spadola A, Yuan E, Kosek J, Jiang L, Hod E, Li K, Murty VV, Schupf N, Vilain E, et al. Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nat Genet 2008; 40:904-8; PMID:18568024; http://dx.doi.org/10.1038/ng.174
7. Schalkwyk LC, Mcbeurn EL, Smith R, Dempster EL, Jeffries AR, Davies MN, Plomin R, Mill J. Allelic skewing of DNA methylation is
widespread across the genome. Am J Hum Genet 2010; 86:196-212; PMID:2059110; http://dx.doi.org/10.1016/j.ajhg.2010.01.014
8. Shoemaker R, Deng J, Wang W, Zhang K. Allele-specific methylation is prevalent and is contributed by CpG-SNPs in the human genome. Genome Res 2010; 20:883-9; PMID:20416090; http://dx.doi.org/10.1101/gr.104695.109
9. Tycko B. Allele-specific DNA methylation: beyond imprinting. Hum Mol Genet 2010; 19:R210-20; PMID:20855472; http://dx.doi.org/10.1093/hmg/ddq376
10. Gertz J, Varley KE, Reddy TE, Bowling KM, Pauli F, Parker SL, Kucera KS, Willard HF, Myers RM. Analysis of DNA methylation in a three-generation family reveals widespread genetic influence on epigenetic regulation. PLoS genetics 2011; 7:e1002228; PMID:21852959; http://dx.doi.org/10.1371/journal.pgen.1002228
11. Bell JT, Pai AA, Pickrell JK, Gaffney DJ, Pique-Rigot R, Degner JF, Gilad Y, Pritchard J. DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome biology 2011; 12:R10; PMID:21251332; http://dx.doi.org/10.1186/gb-2011-12-1-r10
12. Elliott G, Hong C, Xing X, Zhou X, Li D, Coarfa C, Bell RJ, Maire CL, Ligon KL, Sagaroudina M, et al. Intermediate DNA methylation is a conserved signature of genome regulation. Nat Commun 2015; 6:6363; PMID:25691127; http://dx.doi.org/10.1038/ncomms7363
13. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 2007; 447:425-32; PMID:17522676; http://dx.doi.org/10.1038/nature06518
14. Meissner A, Mikkelsen TS, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filatov D, Li X, Wu J, Calabrese A, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 2007; 447:389-95; PMID:17522677; http://dx.doi.org/10.1038/nature05918
15. Seisenberger S, Andrews S, Krueger F, Arand J, Walter J, Santos F, Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, Hanna J, Mill J, Heijmans BT. From promises to practical strategies in epigenomic annotation of the human brain methylome identifies tissue-specific epigenetic variation across brain and blood. Genome Biology 2012; 13:843; PMID:22703893; http://dx.doi.org/10.1186/gb-2012-13-6-r43
16. Takizawa T, Nakashima K, Namihira M, Ochiai W, Uemura A, Yanasawa M, Fujita N, Nakao M, Taga T. DNA methylation is a critical cell-intrinsic determinant of astrocyte differentiation in the fetal brain. Developmental cell 2001; 1:749-58; PMID:11740937; http://dx.doi.org/10.1016/s1534-5807(01)00130-0
17. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filatov D, Li X, Wu J, Calabrese A, et al. Chromatin immunoprecipitation coupled to massively parallel sequencing of DNA from formalin-fixed tissues. Nature 2009; 462:376-81; PMID:19450422; http://dx.doi.org/10.1038/nature08614
18. Zhang X, Bernstein BE, Nusbaum C, Jaffe DB, et al. Genome-scale DNA methylation variation in adipose tissue from twins reveals links to disease-associated variants in distal regulatory elements. Am J Hum Genet 2013; 92:462-74; PMID:23577047; http://dx.doi.org/10.1038/ajhg.2013.10.004
19. Mancini-Dinardo D, Steele SJ, Levorse JM, Mukamel EA, Leung D, Rajagopal N, Nery JR, Urich MA, Chen H, et al. Human body epigenome maps reveal noncanonical DNA methylation variation. Nature 2015; 521(7529):412-6; PMID:26605523; http://dx.doi.org/10.1038/nature16179
20. Prickett AR, Oakley RJ. A survey of tissue-specific genomic imprinting in mammals. Mol Genomics 2012; 5:261-30; PMID:22821278; http://dx.doi.org/10.1017/s175528061200008-0
21. Mill J, Heijmans BT. From promises to practical strategies in epigenomic regulation during mammalian brain development. Science 2013; 341:1237905; PMID:23828890; http://dx.doi.org/10.1126/ science.1237905
22. Williamson CM, Ball ST, Dawson C, Mehta S, Beechey CV, Fray M, Teboul L, Dear TN, Kelsey G, Peters J. Uncoupling antisense-mediated silencing and DNA methylation in the implanted Gnas cluster. PLoS genetics 2011; 7:e1001347; PMID:21455290; http://dx.doi.org/10.1371/journal.pgen.1001347
23. Arnaud P, Monk D, Hitchins M, Gordon E, Dean W, Beechey CV, Peters J, Graigwen W, Preece M, Stanier P, et al. Conserved methylation imprints in the human and mouse Gribio genes with divergent allelic expression suggests differential reading of the same mark. Hum Mol Genet 2003; 12:1005-19; PMID:12700169; http://dx.doi.org/10.1093/hmg/ddg110
24. Grundberg E, Meduri E, Sandling JK, Hedman AK, Keildson S, Buil A, Mill J, Heijmans BT. From promises to practical strategies in epigenomic analysis of DNA methylation variation in adipose tissue from twins reveals links to disease-associated variants in distal regulatory elements. Am J Hum Genet 2013; 93:876-90; PMID:24183450; http://dx.doi.org/10.1016/j.ajhg.2013.10.004
25. Mill J, Heijmans BT. From promises to practical strategies in epigenetic epigenomics. Nat Rev Genet 2013; 14:585-94; PMID:23817309; http://dx.doi.org/10.1038/nrg3405
26. Meaburn EL, Schalkwyk LC, Mill J. Allele-specific methylation in the human genome: implications for genetic studies of complex disease. Epigenetics 2010; 5:578-82; PMID:20761955; http://dx.doi.org/10.4161/epi.5.7.12960
27. Hutchinson NJ, Raj T, Fagerness J, Stahl E, Viloria-Flores, Gimelbrant A, Seddon J, Daly M, Chess A, Plenge R. Allele-specific methylation occurs at genetic variants associated with complex disease. PLoS one
38. Encode Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 2012; 489:57-74; PMID:22955616; http://dx.doi.org/10.1038/nature11247

39. Treppendahl MB, Qiu X, Sogaard A, Yang X, Nandrup-Bus C, Hother C, Andersen MK, Kjeldsen L, Mollgard L, Hellstrom-Lindberg E, et al. Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. Blood 2012; 119:206-16; PMID:22058117; http://dx.doi.org/10.1182/blood-2011-06-362541

40. Romanelli V, Nakabayashi K, Vizoso M, Moran S, Iglesias-Platas I, Sugahara N, Simon C, Hata K, Esteller M, Court F, et al. Variable maternal methylation overlapping the nc886/vtRNA2-1 locus is locked between hypermethylated repeats and is frequently altered in cancer. Epigenetics 2014; 9:783-90; PMID:24589629; http://dx.doi.org/10.4161/epi.28323

41. Illingworth RS, Gruenewald-Schneider U, De Sousa D, Webb S, Merusi C, Kerr AR, James KD, Smith C, Walker R, Andrews R, et al. Inter-individual variability contrasts with regional homogeneity in the human brain DNA methylome. Nucleic Acids Res 2015; 43:732-44; PMID:25572316; http://dx.doi.org/10.1093/nar/gku1305

42. Holt LJ, Siddle K. Grb10 and Grb14: enigmatic regulators of insulin action—and more? Biochem J 2005; 388:393-406; PMID:15901248; http://dx.doi.org/10.1042/BJ20050216

43. Garfield AS, Cowley M, Smith FM, Moorwood K, Stewart-Cox JE, Gilroy K, Baker S, Xia J, Dalley JW, Hurst LD, et al. Distinct physiological and behavioural functions for parental alleles of imprinted Grb10. Nature 2011; 469:534-8; PMID:21270893; http://dx.doi.org/10.1038/nature09651

44. Rusk N, Le PU, Mariggiò S, Guay G, Lurisci C, Nabi IR, Corda D, Symons M. Synaptojanin 2 functions at an early step of clathrin-mediated endocytosis. Curr Biol 2003; 13:659-63; PMID:12699622; http://dx.doi.org/10.1016/S0960-9822(03)00241-0

45. Verstreken P, Koh TW, Schulze KL, Zhai RG, Hiesinger PR, Zhou Y, Mehta SQ, Cao Y, Roos J, Bellien HJ. Synaptojanin is recruited by endophilin to promote synaptic vesicle uncoating. Neuron 2003; 40:733-48; PMID:14622578; http://dx.doi.org/10.1016/S0896-6273(03)00644-5

46. Davis OS, Plomin R, Schlakwyk LC. The SNPMAp package for R: a framework for genome-wide association using DNA pooling on microarrays. Bioinformatics 2009; 25:281-3; PMID:19008252; http://dx.doi.org/10.1093/bioinformatics/btn587

47. Morgan M, Carlson M, Tenenbaum D, Arora S. AnnotationHub: Client to access AnnotationHub resources. R package version 2.2.2.

48. Pohlet T (2014). The Pairwise Multiple Comparison of Mean Ranks Package (PMCMR). R package, http://CRAN.R-project.org/package=PMCMR.

49. Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T. BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics 2005; 21:4067-8; PMID:16141249; http://dx.doi.org/10.1093/bioinformatics/bti652

50. Pidsley R, CC YW, Volta M, Lunnon K, Mill J, Schlakwyk LC. A data-driven approach to preprocessing Illumina 450K methylation array data. BMC genomics 2013; 14:293; PMID:23631413; http://dx.doi.org/10.1186/1471-2164-14-293

51. Lawrence M, Huber W, Pages H, Aboyoun P, Carlson M, Gentleman R, Morgan MT, Carey VJ. Software for computing and annotating genomic ranges. PLoS Comput Biol 2013; 9:e1003118; PMID:23950696; http://dx.doi.org/10.1371/journal.pcbi.1003118